Page 1

verve THERAPEUTICS Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results August 12 , 2021 New Preclinical Base Editing Durability Data and Proprietary GalNAc - targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021 VERVE - 101 IND - Enabling Studies Ongoing to Support Planned IND Submission in 2022 Successful $ 306.7 Million IPO Completed to Enable Advancement of Gene Editing Programs for Cardiovascular Disease CAMBRIDGE , Mass . , Aug. 12 , 2021 ( GLOBE NEWSWIRE ) -- Verve Therapeutics , Inc. , ( Nasdaq : VERV ) , a biotech company pioneering a new approach to the care of cardiovascular disease with single - course gene editing medicines , today reported pipeline and business highlights and second quarter 2021 financial results . " Verve is committed to advancing medicines that can fundamentally change treatment for patients with cardiovascular disease and ultimately , prevent it altogether , " said Sekar Kathiresan , M.D. , co - founder and chief executive officer of Verve . " We have spent the last few years making progress on our mission , and in non - human primate studies , have shown that with just a single treatment of our base editor targeting PCSK9 , we can safely and durably lower disease - causing high LDL cholesterol , a key driver of cardiovascular disease today . I am proud of what we have achieved to date and look forward to the milestones ahead for our programs and the potential impact our therapies could make for millions of patients around the world . " Andrew Ashe , J.D. , president and chief operating officer of Verve added , " Following the completion of our successful IPO in June , we are well capitalized today , with resources to support the advancement of our two lead programs into clinical development , potential expansion of our pipeline and optimization of our technologies . The combination of a compelling pipeline , strong balance sheet and dedicated team , positions Verve to advance gene editing therapies that could transform cardiovascular disease treatment . " Pipeline Highlights • Updated Data from PCSK9 Gene Editing Program and LNP Delivery Approach to be Presented at TIDES 2021 : Verve is scheduled to provide two presentations : ( 1 ) updated preclinical durability data from its lead program targeting PCSK9 , in non - human primates ( NHPs ) ; and ( 2 ) new in vivo data highlighting its proprietary , internal lipid nanoparticle ( LNP ) delivery program ( liver - targeting via incorporation of a novel GalNAc - targeting ligand ) during oral sessions at the TIDES USA Oligonucleotide & Peptide Therapeutics Conference ( TIDES 2021 ) . Details of the presentations are as follows : Title : In vivo CRISPR Base Editing of PCSK9 Durably Lowers Cholesterol in Primates Track : mRNA and Genome Editing TRACK : Genome Editing Advances from Preclinical to the Clinic Date / Time : Thursday , September 23 , 2021 , 8:30 a.m. - 9:00 a.m. ET Title : Targeted Delivery of Base Editors to Hepatocytes In Vivo Track : Oligonucleotide CMC and Targeted Delivery TRACK : Targeted Delivery of Therapeutic Oligonucleotides Date / Time : Thursday , September 23 , 2021 , 8:30 a.m. - 9:00 a.m. ET • Data Demonstrating Potent and Durable Lowering of PCSK9 in NHPs Published in Nature : In May 2021 , Verve published proof - of - concept data highlighting the company's gene editing approach for the treatment of cardiovascular disease in the journal Nature . Data included were from an ongoing preclinical study of the administration of a single gene editing treatment in NHPs . In this study , Verve observed potent and durable lowering of both blood PCSK9 protein and low - density lipoprotein cholesterol ( LDL - C ) levels of approximately 90 % and 60 % , respectively , following administration of a single gene editing treatment . These data showed durability out to 10 months at the most recent analysis . Business Highlights • $ 306.7 Million Initial Public Offering ( IPO ) Successfully Completed : In June 2021 , Verve sold 16,141,157 shares of its common stock , which included 2,105,368 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares , at a public offering price of $ 19.00 per share . Including the option exercise , the aggregate gross proceeds to Verve from the offering were $ 306.7 million , before deducting the underwriting discounts and commissions and offering expenses . • Board of Directors Expanded to Support Future Growth : In the second quarter of 2021 , Verve announced two